Long term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesions

  • Protocol
  • Intervention

Authors


Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

  1. To compare the incidence of gastric premalignant lesions (i.e. atrophic gastritis, intestinal metaplasia and dysplasia) in patients on long-term (≥ 6 months) PPIs with those on no such therapy.

  2. To compare the incidence of gastric premalignant lesions in patients who had long-term PPI therapy with those without such treatment, in association with:

    1. presence of H. pylori infection;

    2. duration, type and dosage of PPI used;

    3. type of the underlying disease that the PPI is prescribed for (e.g. GERD, peptic ulcer disease).

  1. presence of H. pylori infection;

  2. duration, type and dosage of PPI used;

  3. type of the underlying disease that the PPI is prescribed for (e.g. GERD, peptic ulcer disease).